Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp

Diagnostic Microbiology and Infectious Disease
Kyungwon LeeKorean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) group

Abstract

Metallo-beta-lactamase (MBL)-producing Pseudomonas spp. and Acinetobacter spp. were prevalent in Korean hospitals. In this study, the prevalence and presence of MBL-producing isolates among imipenem-nonsusceptible and imipenem-susceptible isolates, respectively, were screened. The genetic and phenotypic characteristics of MBL-producing isolates were determined. Among imipenem-nonsusceptible isolates, 52 (11.1%) of 467 Pseudomonas spp. were blaVIM-like allele-positive, and 33 (15.1%) of 218 Acinetobacter spp. were either blaVIM- or blaIMP-like allele-positive. One blaVIM-like allele-positive isolate of Acinetobacter spp. was detected among 84 imipenem-susceptible Acinetobacter isolates. The minimum inhibitory concentration for 90% of isolates of imipenem was higher (>128 microg/mL) for Pseudomonas spp. than Acinetobacter spp. (16 microg/mL), although both had blaVIM-like allele. The source of MBL-producing isolates was mostly the sputum and urine of patients in the intensive care unit. Pulsed-field gel electrophoresis analysis suggested the intra- and inter-hospital spread of MBL-producing strains at some hospitals. In conclusion, blaVIM-like allele-positive P. aeruginosa remained highly prevalent, and the proportion of blaIMP-l...Continue Reading

References

Jan 1, 1991·Antimicrobial Agents and Chemotherapy·M WatanabeS Mitsuhashi
Feb 1, 1997·Antimicrobial Agents and Chemotherapy·B A Rasmussen, K Bush
Aug 12, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A MazzariolR Fontana
Oct 26, 2000·Current Opinion in Microbiology·D M Livermore, N Woodford
Apr 4, 2002·Diagnostic Microbiology and Infectious Disease·Jong Hwa YumYunsop Chong
Jun 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yoichi HirakataShigeru Kohno

❮ Previous
Next ❯

Citations

Jun 1, 2006·The American Journal of Medicine·John E McGowan
Sep 27, 2005·The Lancet Infectious Diseases·James S Soothill, Paul E Lock
Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert A Bonomo, Dora Szabo
Jul 27, 2007·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Rosângela CiprianoAna Carolina P Vicente
Jan 11, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Alexandros IkonomidisAthanassios Tsakris
Jul 25, 2007·Antimicrobial Agents and Chemotherapy·Federico PerezRobert A Bonomo
Jul 8, 2005·Journal of Clinical Microbiology·Johann D D PitoutDeirdre L Church
Apr 29, 2011·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Ce YangJian-Xin Jiang
Jan 1, 2012·Jundishapur Journal of Natural Pharmaceutical Products·Enayatollah KalantarMohammad Mehdi Soltan Dallal
Sep 18, 2010·Diagnostic Microbiology and Infectious Disease·Saber YousefiNima Hosseini Jazani
May 28, 2008·American Journal of Infection Control·Evelina N Lagamayo
Feb 14, 2012·International Journal of Antimicrobial Agents·Jung Sik YooYeong Seon Lee
Apr 10, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A TsakrisF Markou
Jun 24, 2008·International Journal of Antimicrobial Agents·Helen GiamarellouKyriaki Kanellakopoulou
Jul 4, 2006·American Journal of Infection Control·John E McGowan
Jul 15, 2015·Infection & chemotherapy·Duck Jin HongKyungwon Lee
Mar 1, 2008·The Korean journal of laboratory medicine·Ji Youn SungSun Hoe Koo
Jun 30, 2005·Current Opinion in Infectious Diseases·Shiri Navon-VeneziaYehuda Carmeli
Mar 3, 2010·Expert Review of Anti-infective Therapy·David Felipe BriceñoMaría Virginia Villegas
May 14, 2005·The Journal of Antimicrobial Chemotherapy·Seungok LeeMoon Won Kang
May 15, 2020·Clinical Microbiology Reviews·David M P De OliveiraMark J Walker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.